ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2215

Apoptotic Cell-Based Therapy To Treat Collagen-Induced Experimental Arthritis. Rationale For The Use Of Apoptotic Cells In The Treatment Of Rheumatoid Arthritis

Sylvain Perruche1, Amandine Clauzon1, Francis Bonnefoy1, Eric Toussirot2 and Philippe Saas3, 1UMR1098 INSERM, EFS Bourgogne Franche Comté, Besançon, France, 2Université de Franche Comté , CHRU, CIC Biotherapy 506 and Rheumatology and EA 4266 Pathogens and Inflammation, Besançon, France, 3Etablisement Français du Sang ; Université de Franche Comté, INSERM UMR1098, Besançon, France

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Animal models, Apoptosis, arthritis management and cell therapy, T-Regulatory Cells

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Rheumatoid Arthritis - Animal Models II

Session Type: Abstract Submissions (ACR)

Background/Purpose: Most of the currently available biological agents used in the treatment of rheumatoid arthritis (RA) target a cellular or soluble factor involved in the physiopathology of the disease. Alternatively, cellular therapies are scarce in the therapeutic management of RA. Apoptotic cells display immunologic properties that have been used to resolve inflammation in various experimental models of autoimmune diseases (diabetes, demyelinating diseases) as well as in bone marrow transplantation to favour engraftment and prevent graft versus host disease. Apoptotic cell approach has been successfully assessed to prevent arthritis development in experimental rat model. Here we evaluated a cell-based therapeutic approach based on the immuno-modulatory properties of apoptotic cells to treat RA. In this study, we thus investigated the effects apoptotic cell injection to treat arthritis in a mouse model of collagen-induced arthritis (CIA).

Methods: CIA was induced in susceptible DBA/1 mice using type II bovine collagen immunization. Four to 8 days after arthritis development (d20 post-immunization) mice presenting arthritic symptoms were treated with apoptotic cells (5.10e6 cell/mouse). As control, methotrexate was used (MTX, 15 mg/kg, twice) alone or with apoptotic cells. Regulatory T cells (Treg) were assessed by FACS at time of sacrifice (day 40/45).

Results: Apoptotic cell injection demonstrated a significant decrease of arthritis score (p>0.01; 4 independent experiments), associated with an increased percentage of Treg in the spleen at time of sacrifice (Figure: Apoptotic cell injection in collagen induced arthritis attenuates arthritis score either after early or late injection. Data are obtained in DBA1 mice immunized with bovine type II collagen). In addition, MTX was sufficient to decrease arthritis as well and apoptotic cell injection did not influence MTX efficiency and vice-et-versa. Whereas MTX did not affect the percentage of Treg, MTX + apoptotic cell treatment induced a strong increase of Treg in the spleen and draining lymph nodes.

 

 

 

 

 

 

 

Conclusion: Apoptotic cell injection is an effective treatment to reduce arthritis severity and should be consider in clinic as an alternative method for the treatment of patients with RA. A phase I/II clinical trial using this therapeutic approach is currently planned by our group in patients with RA refractory to biological agents.

 

 

 


Disclosure:

S. Perruche,
None;

A. Clauzon,
None;

F. Bonnefoy,
None;

E. Toussirot,
None;

P. Saas,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/apoptotic-cell-based-therapy-to-treat-collagen-induced-experimental-arthritis-rationale-for-the-use-of-apoptotic-cells-in-the-treatment-of-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology